secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-05-27T13:01:19+00:00
Accession:  0001104659-26-066631
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia announces Phase 1 data: DA-1726 48 mg yields 9.1% weight loss at Day 54 without plateau
--------------------------------------------------------------------------------

- 48 mg cohort achieved 9.1% mean body weight reduction at Day 54; no plateau through Week 8.
- Exploratory FibroScan showed liver improvements: CAP -20.0 dB/m vs +24.0 placebo; liver stiffness -10.3% vs +13.8%.
- No serious adverse events or treatment-related discontinuations; GI events mild-to-moderate and transient.
- Waist circumference reduced by 9.8 cm at Day 54 (p<0.05 vs placebo at Day 26).
- Ongoing Phase 1 Part 3a/3b titration studies evaluate extended treatment at higher doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926066631/0001104659-26-066631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926066631/mtva-20260527x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-066631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer